Clobazam (22316-47-8)

Home » APIs » Clobazam

Clobazam is a 1,5-benzodiazepine, comprising of B ring nitrogen placed in positions 1 and 5 contrary to 1,4-benzodiazepines. It was first synthesized in 1966. Clobazam is a partial GABA receptor agonist, with anxiolytic, sedative, and anticonvulsant activities. It has been marketed as an anxiolytic since 1975 and an anticonvulsant since 1984. The oral preparation was FDA approved on October 21, 2011.

Clobazam is a Schedule IV controlled substance. Common side effects of clobazam include fever, drowsiness, dizziness, drooling, and constipation. In humans, tolerance to the anticonvulsant effects of clobazam may occur and withdrawal seizures may occur during abrupt or over-rapid withdrawal. Clobazam as with other benzodiazepine drugs can lead to physical dependence and addiction, thus causing benzodiazepine withdrawal syndrome.

The product is currently under development. Samples are available from R&D.
Name of Product Clobazam
IUPAC Name 7-chloro-1-methyl-5-phenyl-1,5-benzodiazepine-2,4-dione
Synonyms Frisium, Urbanyl, Chlorepin, Clorepin, Onfi, Urbadan
CAS No 22316-47-8
Molecular Formula C16H13ClN2O2
Molecular Weight 300.74 g/mol
Pubchem CID 2789
Pubchem SID 463577011


SR. No Criteria Limit/Specification
1 Appearance (Color) White to Almost white
2 Appearance (Form) Crystalline Solid
3 Solubility Freely soluble in methylene chloride, Sparingly soluble in ethanol, Slightly soluble in water
4 Solubility
(In Water)
188mg/L (25 °C)
5 Melting Point 162-164°C
5 Density 1.335 g/cm3
6 Uses As an adjunctive therapy in Epilepsy

You can enquire about any of our products/services online.

Our team will get back to you within 24 hours.
Website Designed & Developed By: Webtech Softwares Pvt. Ltd. | Digital Marketing Agency
Copyright © 2014-22 Macsen Laboratories.